Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early conversion from cyclosporine to everolimus in de novo renal transplant recipients
2007-000771-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in Kidney allograft status (RTx) and Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by Novartis. Primary endpoints: Renal function (mGFR) at 12 months post-transplant, Renal function (mGFR) at 36 months post-transplant and 2 more. Started Aug 2007; status: completed.
02
Drugs
everolimus
03
Conditions
Kidney allograft status (RTx)Chronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on 2007-000771-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000771-42.